SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-058700
Filing Date
2021-11-29
Accepted
2021-11-29 17:12:21
Documents
53
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inkt-10q_20210930.htm   iXBRL 10-Q 1828780
2 EX-31.1 inkt-ex311_64.htm EX-31.1 22064
3 EX-31.2 inkt-ex312_63.htm EX-31.2 22912
4 EX-32.1 inkt-ex321_62.htm EX-32.1 10334
  Complete submission text file 0001564590-21-058700.txt   4674260

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA inkt-20210930.xsd EX-101.SCH 29737
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inkt-20210930_cal.xml EX-101.CAL 31083
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inkt-20210930_def.xml EX-101.DEF 62412
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE inkt-20210930_lab.xml EX-101.LAB 240810
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inkt-20210930_pre.xml EX-101.PRE 175277
10 EXTRACTED XBRL INSTANCE DOCUMENT inkt-10q_20210930_htm.xml XML 526562
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40908 | Film No.: 211457237
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences